Back to discover
Drug

Influenza Vaccines

In clinical development
Emerging researchLate-stage developmentSteady momentum

Also known as INFLUENZA, Influenza Virus Vaccine, influenza virus vaccine, unspecified formulation, influenza, unspecified formulation.

RxNorm5806
11
Research papers
2
Active clinical trials
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

FDA Approves First Single-Dose Generic Treatment for Influenza

Regulatory2026-06-17Regulatory news · FDA Press Releases

A Structured Health Assessment in Frequent COPD Exacerbators: To Optimise Management, Identify Comorbidities and Prevent Oral Corticosteroid Related Harm

Clinical trial2026-04-23Results expected Q1 2029 · ClinicalTrials.gov

Influenza Immunization in Adults Over Age 75

Clinical trial2026-03-16Results expected Q4 2026 · ClinicalTrials.gov

A PHASE 1/2, RANDOMIZED, PARTIALLY-BLIND, DOSE-FINDING/DOSE-CONFIRMATION STUDY TO EVALUATE THE SAFETY, REACTOGENICITY AND IMMUNOGENICITY OF THE MRNA-BASED INVESTIGATIONAL PANDEMIC H5 INFLUENZA VACCINE CANDIDATE ADMINISTERED IN HEALTHY YOUNGER AND OLDER ADULTS

Clinical trial2026-01-13Completed · ClinicalTrials.gov

Vaccination as a new form of cardiovascular prevention: a European Society of Cardiology clinical consensus statement.

Research2025-09-01European heart journal

Anti-neuraminidase immunity in the combat against influenza.

Research2024-01-01Expert review of vaccines

Influenza vaccine format mediates distinct cellular and antibody responses in human immune organoids.

Research2023-07-20Immunity

Study of the Non-specific Effects of Influenza and MMR Vaccine on Infectious Diseases in Goiânia, Goiás, Brazil

Clinical trial2022-08-31Completed · ClinicalTrials.gov

The clinical progress of mRNA vaccines and immunotherapies.

Research2022-05-09Nature biotechnology

Effect of Vaccination on Turnover of Lamivudine (3TC) Sensitive and Resistant Virus Populations in HIV-1-Infected Individuals

Clinical trial2021-11-01Withdrawn · ClinicalTrials.gov

Intratumoral Influenza Vaccine for Early Colorectal Cancer

Clinical trial2021-11-01Completed · ClinicalTrials.gov

Influenza Viruses: Innate Immunity and mRNA Vaccines.

Research2021-08-31Frontiers in immunology

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Influenza Vaccines
Aliases & brands
INFLUENZAInfluenza Virus Vaccineinfluenza virus vaccine, unspecified formulationinfluenza, unspecified formulation
RxNorm CUI
5806

Clinical trials

32 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
32
registered trials across all phases
LATEST COMPLETION 2026
2
Active studies
2
Recruiting
23
Late-stage (III+)
28
Completed
2
Discontinued
PHASE DISTRIBUTIONn = 32
Early Phase 11Phase 1 / 22Phase 26Phase 312Phase 47Phase N / A4

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Annual Study for Serum Collection and Evaluation of Safety and Immunogenicity of Fluzone® Influenza Virus Vaccine (2006-2007 Formulation)

CompletedPH IVSanofi Pasteur, a Sanofi Companyn=1162008

Annual Study for Serum Collection and Evaluation of Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Influenza Virus Vaccine (2006-2007 Formulation)

CompletedPH IVSanofi Pasteur, a Sanofi Companyn=312008

Annual Study for Serum Collection and Evaluation of Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Influenza Virus Vaccine (2005-2006 Formulation)

CompletedPH IVSanofi Pasteur, a Sanofi Companyn=302007

A Phase IV, Observer-Blind, Randomized, Parallel Groups, Single-Center, Exploratory Clinical Study to Evaluate the Immunogenicity and Safety of Two 0.25 mL Intramuscular Doses of Three Commercially Available Influenza Vaccines in Healthy Subjects Aged 6 to <36 Months.

CompletedPH IVNovartisn=2702006

Study of the Influence of Immunological Repeated Stimuli With Commercial Vaccines Over the Viral Load (VL), Resistance Development and Specific Immunological Response Against HIV in Early Stage HIV Patients With Undetectable VL After HAART

CompletedPH IVHospital Clinic of Barcelonan=262006

Recent completions

Trials that read out recently, adding to the completed evidence base.

A PHASE 1/2, RANDOMIZED, PARTIALLY-BLIND, DOSE-FINDING/DOSE-CONFIRMATION STUDY TO EVALUATE THE SAFETY, REACTOGENICITY AND IMMUNOGENICITY OF THE MRNA-BASED INVESTIGATIONAL PANDEMIC H5 INFLUENZA VACCINE CANDIDATE ADMINISTERED IN HEALTHY YOUNGER AND OLDER ADULTS

CompletedPH I/IIGlaxoSmithKlinen=9912026

Study of the Non-specific Effects of Influenza and MMR Vaccine on Infectious Diseases in Goiânia, Goiás, Brazil

CompletedPH IRadboud University Medical Centern=6382022

Intratumoral Influenza Vaccine for Early Colorectal Cancer

CompletedPH IIZealand University Hospitaln=102021

A Double-Blind, Randomized, Placebo-Controlled Study of Antibody Induction by Vitamin Supplementation at the Time of Influenza Virus Vaccinations in Children

CompletedPH IISt. Jude Children's Research Hospitaln=872018

Safety and Immunogenicity Trial of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Subjects Aged 65 Years and Older

CompletedPH IISanofi Pasteur, a Sanofi Companyn=7922016

The Phase Ⅲ Clinical Trial Protocol for the Influenza Virus Vaccine (Split Virion, Inactivated)

CompletedPH IIIKey trialInstitute of Medical Biology, Chinese Academy of Medical Sciencesn=1,2002012

Research activity

11 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
20062025
Major research themes8
Influenza Vaccines3Influenza, Human2Adjuvants, Immunologic1Antibodies, Monoclonal1Antibodies, Viral1Cardiovascular Diseases1COVID-191Epstein-Barr Virus Infections1
Journals, researchers & institutions
Top journals
  • Frontiers in immunology2
  • Circulation1
  • eLife1
  • Epidemiology and infection1
  • European heart journal1
  • Expert review of vaccines1
Leading researchers
  • Ahuja G1
  • Allen J1
  • Amir O1
  • Anderson DG1
  • Barbier AJ1
  • Bedford T1
  • Benchorin AI1
  • Blair SN1
Leading institutions
free-text, unnormalised
  • 1250 South Collegeville Road1
  • Atascadero State Hospital1
  • Berlin Institute of Health (BIH) at Charité - Universitätsmedizin Berlin1
  • Brigham and Women's Hospital1
  • Center for Molecular Cardiology1
  • Center for Vaccines and Immunology1

Related diseases

2 conditions

Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.

Active research areas
Influenza, Human6COVID-192

Related drugs

4 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Vitamin D

Studied across 6 of the same disease areas as Influenza Vaccines in the shared literature.

6 shared diseases1 shared paper
COVID-19 Vaccines

Studied across 4 of the same disease areas as Influenza Vaccines in the shared literature.

4 shared diseases2 shared papers
Polysorbates

Studied across the same disease area as Influenza Vaccines in the shared literature.

1 shared disease1 shared paper
Squalene

Studied across the same disease area as Influenza Vaccines in the shared literature.

1 shared disease1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials